Who are F2G's investors?

F2G's investors include Advent Life Sciences, Aisling Capital, AMR Action Fund, Astellas Venture Management LLC, Brace Pharma, Sofinnova Partners, Sunstone Capital, Forbion and 2 more.

How much funding has F2G raised?

F2G has disclosed $160M raised across 2 of its 3 known rounds.

F2G

12 known investors

Find your way into F2G

F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective. The company operates an early access program to provide investigational therapies to qualified patients with life-threatening fungal infections who are ineligible for clinical trials or lack suitable alternative treatment options.

Biotech Digital Health Healthtech Medical Devices

Investors · 12

Advent Life Scienceslisted by Advent Life SciencesLondon

How we know: Advent Life Sciences's portfolio page · funding news · Not right? Tell us

Aisling Capitallisted by Aisling CapitalNew York

How we know: Aisling Capital's portfolio page · Not right? Tell us

AMR Action Fundlisted by AMR Action FundBoston

How we know: AMR Action Fund's portfolio page · funding news · Not right? Tell us

Astellas Venture Management LLClisted by Astellas Venture Management LLCSouth San Francisco · $200K – $5M

How we know: Astellas Venture Management LLC's portfolio page · Not right? Tell us

Brace Pharmalisted by Brace PharmaAtlanta

How we know: Brace Pharma's portfolio page · Not right? Tell us

Sofinnova Partnerslisted by Sofinnova PartnersParis · $540K – $27M

How we know: Sofinnova Partners's portfolio page · a partner's Signal profile · funding news · Not right? Tell us

Sunstone Capitallisted by Sunstone CapitalFrederiksberg

How we know: Sunstone Capital's portfolio page · funding news · the VCSheet dataset · Not right? Tell us

ForbionreportedNaarden

How we know: a partner's Signal profile · funding news · Not right? Tell us

Merifin CapitalreportedBrussels · $216K – $3.2M

How we know: funding news · Not right? Tell us

Novartis Venture FundreportedBasel · $5M – $25M

How we know: a partner's Signal profile · funding news · Not right? Tell us

Also in the syndicate · 2

NovartisNovo

Funding

SEC filings, press & company announcements

$160M disclosed across 2 of 3 rounds · 2016–2024

$100MraisedSep 2024 · 2 sources
Source ↗
$60MraisedJun 2016 · 2 sources
Novartis, Novo
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

F2G Raises $70M in Financingfinsmes.com · Aug 2022

Frequently asked questions

What does F2G do?: F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective. The company operates an early access program to provide investigational therapies to qualified patients with life-threatening fungal infections who are ineligible for clinical trials or lack suitable alternative treatment options.
Who are F2G's investors?: F2G's investors include Advent Life Sciences, Aisling Capital, AMR Action Fund, Astellas Venture Management LLC, Brace Pharma, Sofinnova Partners, Sunstone Capital, Forbion and 2 more.
How much funding has F2G raised?: F2G has disclosed $160M raised across 2 of its 3 known rounds.